Citations

Clear

3138 citation(s) found for "Smith, AM".

Identification and characterization of macrophage regulatory cells (Mac-regs) with immunoregulatory properties (89.38)
Manrique, Soraya Zorro, Mirza, Noweeda, Smith, Shannon E., Lustgarten, Joseph, Duque‐Correa, Maria A. , Dominguez, Ana Lucía , Hoelzinger, Dominique B.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: Supplement_1 | Pages: 89.38-89.38

10.4049/jimmunol.182.supp.89.38 Get It

Abstract Macrophages with suppressive characteristics such as Tumor associated macrophages or Myeloid derived suppressor cells have been defined showing regulatory function under inflammatory or polarizing conditions. Until now, there are no reports indicating that under normal, non-inflammatory or non-polarizing conditions, macrophages could have immunoregulatory functions. Utilizing knock-in Foxp3-GFP mice, we identified a new population of Foxp3 positive cells that were CD11b+F4/80+ cells. These cells were observed in spleen, lymph nodes, bone marrow and thymus. Similar to Tregs, the CD11b+F4/80+Foxp3+ macrophages inhibited T cell proliferation, whereas Foxp3neg macrophages did not. The Foxp3neg macrophages could be converted to express Foxp3. These induced-CD11b+F4/80+Foxp3+ cells displayed inhibitory properties similar to natural Foxp3pos macrophages. Based on the immunoregulatory properties of these cells, we termed them Macrophage regulatory cells (Mac-regs). These Mac-regs express CD68hiF4/80hiCTLA4hiGITRhiIL-4Rhi. Interestingly, GR-1 is not a differentiation marker. The cytokine, chemokine, growth factor and genomic profiles of Mac-regs are different compared to CD11b+F4/80+Foxp3-cells. For the first time, we demonstrated the occurrence of a natural population of macrophages displaying regulatory function which may contribute to the homeostatic balance of the immune system. This research was supported by Grants from the NIH and AFAR.
NKAP, a novel modulator of Notch signaling, is required for T cell development (85.5)
Pajerowski, Anthony G., Nguyen, Chau , Shapiro, Michael J. , Shapiro, Virginia Smith , Aghajanian, Haig , Shapiro, Michael J

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 85.5-85.5

10.4049/jimmunol.182.supp.85.5 Get It

Abstract T cell development depends on the coordinated interplay between receptor signaling and transcriptional activation/repression. We performed a genetic complementation screen, and identified a novel transcriptional repressor, NKAP. NKAP associates with HDAC3 and is part of a DNA-binding complex, as shown by chromatin immunoprecipitation. NKAP also associates with CIR, a part of the Notch corepressor complex. The expression of NKAP during T cell development inversely correlates with the expression of Notch target genes, implying that NKAP may modulate Notch-mediated transcription. To examine the function of NKAP in T cell development, Lck-cre NKAP conditional knockout mice were generated. Interestingly, loss of NKAP blocks development of alpha/beta but not gamma/delta T cells. In addition, lck-cre NKAP cKO DP T cells express 8- to 20-fold higher levels of Hes1, Deltex1 and CD25, providing in vivo evidence that NKAP functions as a transcriptional repressor, acting at least in part, by repression of the Notch pathway.
Severe block in hematopoiesis in the absence of NKAP (138.2)
Pajerowski, Anthony G., Shapiro, Michael J. , Shapiro, MIchael J, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 138.2-138.2

10.4049/jimmunol.182.supp.138.2 Get It

Abstract During hematopoiesis, proper differentiation of the long-term, multi-potent, self-renewing hematopoietic stem cell (HSC) results in the cellular components of blood. The lineage fate decisions that occur during hematopoiesis result from the coordinated regulation of transcriptional activators, repressors, and chromatin modifiers. We have identified NKAP as a novel regulator of hematopoiesis, that functions at least in part as a transcriptional repressor. In this study we employ a combination of conditional and inducible mouse models of NKAP deletion to explore the role of NKAP in hematopoietic development starting at the HSC stage. Our models allow for both the pan-deletion of NKAP starting in the HSC stage by using a vav-cre transgenic, as well as temporally regulated deletion of NKAP in the hematopietic compartment through the use of the interferon-inducible mx1-cre model system. These complimentary approaches allow us to conclude that NKAP functions in a cell intrinsic manner, as a member of a unique group of transcriptional regulators, and is necessary in the earliest stage of definitive hematopoiesis.
CCL1: a novel therapeutic target for the modulation of Treg function: Implications for immmunotherapy of cancer (40.10)
Smith, Shannon E., Manrique, Soraya Zorro, Lustgarten, Joseph, Hoelzinger, Dominique B. , Dominguez, Ana Lucía

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 40.10-40.10

10.4049/jimmunol.182.supp.40.10 Get It

Abstract Effective anti-tumor immunotherapy must overcome the immunosuppressive networks created by the tumor. Previous studies from our group indicate that intratumoral injection of CpG-ODN reduces Treg levels within the tumor by 80%. This decrease in Tregs is mainly mediated by the activation of antigen presenting cells secreting IL-6. To explore the effect of IL6 on Tregs, an expression microarray analysis of genes involved in TGFÎ2 dependent Treg conversion, which are also sensitive to IL6, was done. It yielded gene candidates which can be exploited to modulate the function of Tregs. In vitro analysis of two such candidates: chemokine ligand 1 (CCL1) and integrinαE (ITGαE), shows that blocking these proteins reduces de novo conversion of Tregs (CCL1 and ITGαE) and inhibits the suppressive function of Tregs (CCL1 only). In vivo assays using the neu tolerant breast cancer mouse model demonstrates that injection of αCCL1 or αITGαE blocking antibodies significantly reduced the level of Tregs within the tumor and the tumor draining lymph nodes. Furthermore, the combination of intratumoral injections of CpG-ODN and αCCL1 induce complete tumor rejection in neu mice. These results demonstrate that blockage of CCL1 signaling modulated the function of Tregs and subsequently enhances immunotherapeutic approaches.
Combination of CpG-ODN+anti-4-1BB but not CpG-ODN+anti-OX40 enhances antitumor immune responses in neu mice modulating the inhibitory function of Tregs (40.7)
Smith, Shannon E., Lustgarten, Joseph, Hoelzinger, Dominique B. , Dominguez, Ana Lucía

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 40.7-40.7

10.4049/jimmunol.182.supp.40.7 Get It

Abstract Previous studies have established that 4-1BB and OX40, members of the TNFR family, enhance antitumor immune responses. Recent studies from our laboratory indicate that intratumoral injections of CpG-ODN induce antitumor responses in Her-2/neu tolerant mice. However, this treatment alone is not sufficient to completely eradicate tumors. Here we investigate whether the combination of CpG+anti-OX40 or anti-4-1BB enhance the antitumor responses in neu mice. Our results indicate that CpG+anti-4-1BB but not CpG+anti-OX40 eradicate tumor in neu mice. CpG+anti-4-1BB treatment significantly increased the number of CD8 cells within lymphoid organs as compared to control or anti-OX40 treated animals. More importantly, we observed that anti-4-1BB but not anti-OX40 inhibits the suppressive function of Tregs. Microarray analysis of Tregs revealed specific transcriptional differences brought about by treatment with anti-OX40 or anti-4-1BB. 4-1BB modulates differential gene expression in Tregs of over 300 genes that remain unaffected by OX40. Potential gene candidates include interleukin-9 and protein-tyrosine phosphatase receptor-type zeta-1, which are transcriptionally down and up regulated in the presence of anti-4-1BB. These proteins may play a role in Treg function, and could explain the enhanced anti-tumor effect observed in the presence of anti-4-1BB.
Dissociation Between IFN-α-Induced Anti-Viral and Growth Signaling Pathways
Arora, Taruna , Floyd-Smith, Georgia, Espy, Mark J., Jelinek, Diane F.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 162 | Issue: 6 | Pages: 3289-3297

10.4049/jimmunol.162.6.3289 Get It

Abstract The ability of IFN-α to induce an anti-viral state in a wide variety of cell types as well as to inhibit cellular growth has long been appreciated. It is less clear, however, whether both these effects lie downstream of a common signaling pathway. In this study we have taken advantage of an atypical human myeloma cell line (KAS-6/1) displaying a dramatic proliferative response to IFN-α in an effort to resolve the signaling requirements for IFN-α-induced anti-viral and growth regulatory effects. Thus, we have analyzed the ability of IFN-α to induce a number of known receptor-initiated events in this cell line and have compared these responses with those exhibited by a cell lineage- and maturation stage-matched myeloma cell line (ANBL-6) that displays typical IFN-α responsiveness. Despite the widely contrasting effects of IFN-α on cellular proliferation, IFN-α was shown to be comparable in its ability to induce the expression of early response genes as well as induce resistance to viral infection in both cell lines. By contrast, the effects of IFN-α on the activation of mitogen-activated protein kinase (MAPK) were strikingly distinct. Finally, although inhibition of MEK and MAPK activation had no effect on the induction of the anti-viral response, it completely blocked IFN-α-stimulated proliferation of the KAS-6/1 cells. In summary, our analysis of the role of the MAPK and anti-viral signaling pathways using these two cell lines suggests that the anti-viral and growth regulatory effects of IFN-α display a differential requirement for activation of the MAPK pathway.
Modeling Diagnostic Expertise in Cases of Irreducible Uncertainty: The Decision-Aligned Response Model
Cook, David A. , Friedman, Julie , Lorin, Jeffrey D., Rosenzweig, Barry P., Tong, Calvin Ka Wing, Smith, Silas W. , Pusic, Martin V , Pusic, Martin , Lineberry, Matthew , Hatala, Rose

Mayo Clinic

Academic Medicine | December 28, 2022 | Volume: 98 | Issue: 1 | Pages: 88-97

10.1097/acm.0000000000004918 | PMID 36576770 Get It

Abstract Purpose Assessing expertise using psychometric models usually yields a measure of ability that is difficult to generalize to the complexity of diagnoses in clinical practice. However, using an item response modeling framework, it is possible to create a decision-aligned response model that captures a clinician’s decision-making behavior on a continuous scale that fully represents competing diagnostic possibilities. In this proof-of-concept study, the authors demonstrate the necessary statistical conceptualization of this model using a specific electrocardiogram (ECG) example. Method The authors collected a range of ECGs with elevated ST segments due to either ST-elevation myocardial infarction (STEMI) or pericarditis. Based on pilot data, 20 ECGs were chosen to represent a continuum from “definitely STEMI” to “definitely pericarditis,” including intermediate cases in which the diagnosis was intentionally unclear. Emergency medicine and cardiology physicians rated these ECGs on a 5-point scale (“definitely STEMI” to “definitely pericarditis”). The authors analyzed these ratings using a graded response model showing the degree to which each participant could separate the ECGs along the diagnostic continuum. The authors compared these metrics with the discharge diagnoses noted on chart review. Results Thirty-seven participants rated the ECGs. As desired, the ECGs represented a range of phenotypes, including cases where participants were uncertain in their diagnosis. The response model showed that participants varied both in their propensity to diagnose one condition over another and in where they placed the thresholds between the 5 diagnostic categories. The most capable participants were able to meaningfully use all categories, with precise thresholds between categories. Conclusions The authors present a decision-aligned response model that demonstrates the confusability of a particular ECG and the skill with which a clinician can distinguish 2 diagnoses along a continuum of confusability. These results have broad implications for testing and for learning to manage uncertainty in diagnosis.
Lack of radiosensitivity predicts poor disease specific survival in myxoid liposarcoma
Houdek, Matthew T. , Mallett, Katherine E. , Heidenreich, Mark J. , Ahmed, Safia K. , Wenger, Doris E. , Smith, John-Rudolph H. , Folpe, Andrew L. , Petersen, Ivy A. , Rose, Peter S. , Smith, John R. , Houdek, Matthew T , Smith, John-Rudolph , Siontis, Brittany L. , Robinson, Steven I.

Mayo Clinic

Journal of Surgical Oncology | December 27, 2022 | Volume: 127 | Issue: 5 | Pages: 848-854

10.1002/jso.27190 | PMID 36573830 Get It

AbstractBackgroundCompared to other sarcomas, myxoid liposarcoma (ML) is known to be radiosensitive, with improved oncologic outcomes. Although these tumors “shrink” following radiotherapy, there is a paucity of data examining the degree of radiosensitivity and oncologic outcome. The purpose of the study was to evaluate pre‐ and postradiotherapy tumor volume to determine if size reduction impacts outcome.MethodsWe reviewed 62 patients with ML undergoing surgical resection combined with preoperative radiotherapy, with pre‐ and postradiotherapy MRI. This included 34 (55%) males, with a mean age of 47 ± 14 years. All tumors were deep to the fascia, and 12 (19%) patients had tumors with a >5% round‐cell component.ResultsThe mean volume reduction was 54% ± 29%. Compared to patients with >25% volume reduction, patients with reduction ≤25% had worse 10‐year disease specific survival (86% vs. 37%, p < 0.01), in addition to an increased risk of metastatic disease (HR 4.63, p < 0.01) and death due to disease (HR 4.52, p < 0.01).ConclusionLack of volume reduction is a risk factor for metastatic disease and subsequent death due to disease in patients with extremity ML treated with combined preoperative radiotherapy and surgery. This data could be used to stratify patients for adjuvant therapies and follow‐up intervals.
Demographics of first‐time donors returning for donation during the pandemic: COVID‐19 convalescent plasma versus standard blood product donors
Buren, Nancy L. Van , Rajbhandary, Srijana , Reynolds, Vanessa, Gorlin, Jed B. , Stramer, Susan L. , Notari, Edward P. , Conti, Galen , Katz, Louis M. , Stubbs, James R. , Buskirk, Camille M. van , Kuttner, Kip, Smith, Debra L. , Ngamsuntikul, Samantha, Pandey, Suchitra , Ward, Dawn C. , Ziman, Alyssa , Hiskey, Matthew , Townsend, Mary , Sachais, Bruce S. , van Buren, Nancy L , van Buskirk, Camille M, Ziman, Alyssa , Rajbhandary, Srijana , Gorlin, Jed

Mayo Clinic

Transfusion | December 23, 2022 | Volume: 63 | Issue: 3 | Pages: 552-563

10.1111/trf.17229 | PMID 36550639 Get It

AbstractBackgroundPrevious studies have demonstrated low first‐time donor return rates (DRR) following catastrophic events. Little is known, however, about the influence of demographic factors on the DRR of first‐time donors during the COVID‐19 pandemic, including the unique motivation of COVID‐19 convalescent plasma (CCP) donors as compared to non‐CCP donors.Study Design and MethodsThirteen blood collection organizations submitted deidentified data from first‐time CCP and non‐CCP donors returning for regular (non‐CCP) donations during the pandemic. DRR was calculated as frequencies. Demographic factors associated with returning donors: race/ethnicity, gender, and generation (Gen Z: 19–24, Millennial: 25–40, Gen X: 41–56, and Boomer: ≥57 years old), within the CCP and non‐CCP first‐time cohorts were compared using chi‐square test at p < .05 statistical significance.ResultsFrom March 2020 through December 2021, there were a total of 44,274 first‐time CCP and 980,201 first‐time non‐CCP donors. DRR were 14.6% (range 11.9%–43.3%) and 46.6% (range 10.0%–76.9%) for CCP and non‐CCP cohorts, respectively. Age over 40 years (Gen X and Boomers), female gender, and White race were each associated with higher return in both donor cohorts (p < .001). For the non‐CCP return donor cohort, the Millennial and Boomers were comparable.ConclusionThe findings demonstrate differences in returning donor trends between the two donor cohorts. The motivation of a first‐time CCP donor may be different than that of a non‐CCP donor. Further study to improve first‐time donor engagement would be worthwhile to expand the donor base with a focus on blood donor diversity emphasizing engagement of underrepresented minorities and younger donors.
Impact of Persistent Iatrogenic Atrial Septal Defect following MitraClip
Seri, Amith Reddy , Abraham, Bishoy, Farina, Juan M. , Fennelly, Evelyn , Campany, Megan , Pereyra, Milagros , Said, Ebram F, Kenyon, Courtney , Fath, Ayman R. , Smith, Sean D. , Buckner‐Petty, Skye , Rayfield, Corbin, Fortuin, David, Sweeney, John P., Eleid, Mackram F. , Rihal, Charanjit S. , Holmes, David R. , Pollak, Peter , Sabbagh, Abdallah El , Oh, Jae K. , Arsanjani, Reza , Seri, Amith , Farina, Juan M , Pereyra, Milagros , Smith, Sean , Buckner-Petty, Skye, Rayfield, Corbin A, Pollak, Peter M, Arsanjani, Reza , Kenyon, Courtney R , Chao, Chieh‐Ju , Abraham, Bishoy , Yang, Eric H. , Alkhouli, Mohamad , Rihal, Charanjit S.

Mayo Clinic

Journal of Cardiovascular Development and Disease | December 23, 2022 | Volume: 10 | Issue: 1 | Pages: 1

10.3390/jcdd10010001 | PMID 36661896 Get It

Background: Prior studies have reported conflicting results of persistent iatrogenic atrial septal defect (iASD) and its impact following a transcatheter edge-to-edge repair (TEER) procedure. This study aims to evaluate the incidence of iASD and its clinical and hemodynamic impact after a TEER. Methods: Consecutive patients who underwent a TEER procedure from June 2014 to September 2020 at the Mayo Clinic were identified. The presence of iASD was retrospectively identified on post-procedure transthoracic echocardiography (TTE) to group patients into an iASD+ group and an iASD− group for comparison of prognosis and cardiac function. Results: A total of 316 patients were included; the mean age was 79.1 ± 9.1 years, and 67.7% were male. Persistent iASD was diagnosed in 108 (34.2%) patients. There was no difference concerning all-cause mortality, heart failure hospitalization, and stroke/TIA between groups at follow-up (median follow-up of 9 months). Post-procedure TTE demonstrated no differences regarding right ventricle (RV) and left ventricle (LV) dimensions and function, including TAPSE (15.2 ± 4.6 vs. 15.4 ± 5.5 mm, p = 0.875), and LV ejection fraction (51.1 ± 14.0% vs. 51.3 ± 13.9%, p = 0.933). However, patients with iASD had higher RV systolic pressure (48.7 ± 14.4 vs. 45.5 ± 14.5 mmHg, p = 0.042) compared with patients without iASD. Conclusion: Notwithstanding higher RV pressures, patients with persistent iASD had no hemodynamic compromise and an equal prognosis compared with those without a residual atrial defect after a TEER procedure. These findings support the mid-term safety of procedures in which an interatrial defect needs to be created and would argue against the need for interventional closure.